Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153854 | 0.90 | BACE1 (0.62) | BACE1CYP2D6BACE2APP | |
| Hydrochloric Acid SCHEMBL2154146 | 0.90 | BACE1 (0.61) | BACE1CYP2D6BACE2APP | |
| SCHEMBL2154102 | 0.89 | BACE1 (0.79) | BACE1CYP2D6BACE2APP | |
| SCHEMBL15361970 | 0.86 | BACE1 (0.56) | BACE1CYP2D6BACE2APP | |
| SCHEMBL17200055 | 0.85 | BACE1 (0.64) | BACE1CYP2D6BACE2APP | |
| SCHEMBL17210703 | 0.85 | BACE1 (0.64) | BACE1CYP2D6BACE2APP | |
| SCHEMBL12496806 | 0.85 | BACE1 (0.64) | BACE1CYP2D6BACE2APP | |
| SCHEMBL2154072 | 0.84 | BACE1 (0.66) | BACE1CYP2D6BACE2APP | |
| Hydrochloric Acid SCHEMBL2154301 | 0.83 | BACE1 (0.65) | BACE1CYP2D6BACE2APP | |
| SCHEMBL2154190 | 0.82 | BACE1 (0.73) | BACE1BACE2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | claimed |
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2519515-B1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-11-01 | — | — | US | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885CYP2D6 2438/4885BACE2 1/4885 |
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | BACE1 436/4885CYP2D6 113/4885BACE2 736/4885 |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | BACE1 353/4885CYP2D6 114/4885BACE2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.